Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900050 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2 study, sponsored by Genfit.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05900050 is a Phase 2 study that was terminated before completion, run by Genfit. The registered enrollment target is 15 participants.
The verdict
NCT05900050, a Phase 2 study, was terminated before completion, sponsored by Genfit.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
Interventions
- DRUG VS-01 on top of SOC
- OTHER SOC (Control Group)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-07-02 |
| Est. Completion | 2025-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05900050
The ClinicalTrials.gov registry entry for NCT05900050 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genfit, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VS-01 on top of SOC is the first listed.
NCT05900050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05900050 about?
NCT05900050 is a clinical study titled "Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®". A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Fa...
What is the current status of trial NCT05900050?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-07-02. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT05900050?
The interventions under investigation include: VS-01 on top of SOC (DRUG), SOC (Control Group) (OTHER).
Who is sponsoring clinical trial NCT05900050?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.